| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Department Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany; and
Department of Internal Medicine III, Medical School Ulm, Ulm, Germany
1Correspondence: Abteilung "Molekulare Genetik" (B060),Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany. E-mail: m.macleod{at}dkfz.de
ABSTRACT
A broad range of malignant diseases, such as mantle cell lymphoma (MCL), is associated with complex genomic alterations, demanding multimodal functional testing of candidate genes. To assess such candidate disease genes, we have developed a bidirectional targeted transgenesis tool, which allows well-controlled modulation of individual gene activities within a cellular MCL system. The engineered versatile transgenesis system permits functional analysis of virtually any candidate gene: for tumor suppressor genes by complementation via integration of respective genomic DNA or for oncogenes by inactivation via integrated shRNA coding plasmids. Complementation by genomic DNA ensures wild-type (WT) regulated gene expression, whereas genomic integration of shRNA coding inserts by an advanced RNAi-strategy mediates specific knock-down of gene expression. Site-specific genomic integration of an unmodified BAC, which contains the CDKN2A/B genes absent in the MCL model system, restored CDKN2A/B expression resulting in the inhibition of cell proliferation. CCND1, strongly overexpressed in the model system, was down-regulated via shRNA expression, again inhibiting proliferation. Notably, the presented site-specific shRNA-strategy circumvents interference by IFN-response induced when using other RNAi gene knock-down methods. In conclusion, we here demonstrate that adequate restoration of a range of different gene activities yields in a desired antiproliferative effect in MCL-derived cells. By antagonizing inactivated tumor suppressor genes or activated oncogenes, the presented approach can be readily used for the functional analysis of a broad range of disease-related genetic defects.— Pscherer, A., Schliwka, J., Wildenberger, K., Mincheva, A., Schwaenen, C., Döhner, H., Stilgenbauer, S., Lichter, P. Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphoma.
This article has been cited by other articles:
|
|
 |
|
  S. Wang, Y. Zhao, M. A. Leiby, and J. Zhu Studying human telomerase gene transcription by a chromatinized reporter generated by recombinase-mediated targeting of a bacterial artificial chromosome Nucleic Acids Res., September 1, 2009; 37(17): e111 - e111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heck, J. Rom, V. Thewes, N. Becker, B. Blume, H. P. Sinn, U. Deuschle, C. Sohn, A. Schneeweiss, and P. Lichter Estrogen-Related Receptor {alpha} Expression and Function Is Associated with the Transcriptional Coregulator AIB1 in Breast Carcinoma Cancer Res., June 15, 2009; 69(12): 5186 - 5193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ortega-Paino, J. Fransson, S. Ek, and C. A. K. Borrebaeck Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference Blood, February 1, 2008; 111(3): 1617 - 1624. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
